Dennis Robert J
Known title: DirectorCIK: 0001295441
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
CoreCivic Sets Q3 2026 Earnings Date Amid Sector News. CoreCivic announced the dates for its 2026 third-quarter earnings release and conference call. This announcement appears alongside broader industry news, including a $950 million deal where the Department of Homeland Security purchased three detention facilities from The Geo Group. The stock is currently trading near its support level, with analysts maintaining an average price target of $41.80.
Transaction History
| HCA | ▲ Buy | Grant | 1,026 | $0 | 4/29/2025 | View on chart |
| CXW | ▲ Buy | Grant | 8,098 | $0 | 2/19/2025 | View on chart |
| CXW | ▼ Sell | Open Market | 20,000 | $440K | 11/13/2024 | View on chart |
| HCA | ▲ Buy | Grant | 963 | $0 | 4/29/2024 | View on chart |
| CXW | ▲ Buy | Grant | 9,247 | $0 | 2/16/2024 | View on chart |
| HCA | ▲ Buy | Grant | 1,047 | $0 | 4/24/2023 | View on chart |
| CXW | ▲ Buy | Grant | 12,784 | $0 | 2/17/2023 | View on chart |
| HCA | ▲ Buy | Grant | 902 | $0 | 4/25/2022 | View on chart |
| CXW | ▲ Buy | Grant | 13,720 | $0 | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns
HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns. HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.